MicroRNA Expression Profiles in Serous Ovarian Carcinoma

By E. Nam, Heejei Yoon, Sang Wun Kim, Hoguen Kim, Young Tae Kim, Jae Hoon Kim, Jae Wook Kim, Sunghoon Kim. Clinical Cancer Research, 2008

786 citations recorded by the source corpus.

Purpose: Although microRNAs have recently been recognized as riboregulators of gene expression, little is known about microRNA expression profiles in serous ovarian carcinoma. We assessed the expression of microRNA and the association between microRNA expression and the prognosis of serous ovarian carcinoma. Experimental Design: Twenty patients diagnosed with serous ovarian carcinoma and eight patients treated for benign uterine disease between December 2000 and September 2003 were enrolled in this study. The microRNA expression profiles were examined using DNA microarray and Northern blot analyses. Results: Several microRNAs were differentially expressed in serous ovarian carcinoma compared with normal ovarian tissues, including miR-21, miR-125a, miR-125b, miR-100, miR-145, miR-16, and miR-99a, which were each differentially expressed in >16 patients. In addition, the expression levels of some microRNAs were correlated with the survival in patients with serous ovarian carcinoma. Higher expression of miR-200, miR-141, miR-18a, miR-93, and miR-429, and lower expression of let-7b, and miR-199a were significantly correlated with a poor prognosis (P < 0.05). Conclusion: Our results indicate that dysregulation of microRNAs is involved in ovarian carcinogenesis and associated with the prognosis of serous ovarian carcinoma.

Subfields: Cancer Research, Molecular Biology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/6565d4d3b96107f1697a56e0c275732e1d13563c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Reproductive Medicine

Citations in the corpus

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. (2009, background): “Over-expression of miR-93 was associated with decreased progression-free and overall survival in ovarian cancer patients [13].”
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization (2011, result): “These findings are consistent with a clinical correlation observed in individuals with serous ovarian carcinom”
miR-21: a small multi-faceted RNA (2008, background): “[3, 53, 58, 60] Ovarian cancer Up-regulation [6, 7] Colorectal cancer Up-regulation Cellular outgrowth, migration, invasion and metastasis PDCD4, NFIB, SPRY2 [3, 25, 52, 86] Stomach/gastric cancer Up-regulation RECK [3, 5] Hepatocellular carcinoma Up-regulation Cell migration and invasion and…”
MicroRNA-125b is a novel negative regulator of p53. (2009, background): “In fact, the rescue GENES & DEVELOPMENT 867 effects of miR-125b duplex during the DNA damage response were nearly as great as the effects of p53 knockdown via a morpholino (Fig.”
The mammalian ovary from genesis to revelation. (2009, background): “For women with ovarian cancer, the identification of miRNA-related biomarkers is still in its infancy, but the early data have revealed several candidates whose expression in ovarian tumors portends prolonged ( ) or diminished ( ) survival, for example, let-7( ), mir-200( ), mir-93( ), and the eight”
MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, positive): “In ovarian, thyroid, and oral squamous-cell carcinomas, miR-125b is downregulated and has been shown to inhibit cell proliferation and cell-cycle progression”
The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? (2010, background): “…Low expression of miR-200a/b/429 correlates with poor survival miR-200 upregulated in ovarian cancer High expression of miR-200 correlates with poor prognosis Hu et al, 2009 Nam et al, 2008 Bendoraite et al, 2010 miR, microRNA; NSCLC, non-small-cell lung cancer; ZEB, zinc-finger enhancer binding.”